On this page

Pharma direct-to-patient programs are drugmaker-run channels that let a patient pay a cash price for a prescription drug and get it filled and delivered through partner pharmacies, often after a telehealth visit and outside the pharmacy benefit. L.E.K. Consulting's Figure 1 lists 11 manufacturer platforms, including LillyDirect, NovoCare Pharmacy and PfizerForAll (L.E.K.), and TrumpRx.gov, launched on February 5, 2026, connects patients with manufacturers' offers (White House). This guide from Curve Compliance covers who runs them, when they launched, who does what inside a program, and what the OIG's January 27, 2026 bulletin covers.

Book a call. Measuring a direct-to-patient program? See how partner step events become aggregate results by channel, campaign and partner, with cost per paid fill by campaign against your Meta and Google Ads spend. Book a call with Curve.

What are pharma direct-to-patient programs?

pharmaphorum's column by DiMe chief executive Jennifer C Goldsack defines a direct-to-patient platform as “a digitally enabled, end-to-end treatment model in which pharmaceutical companies and their partners deliver [...] prescribing, medication access, and longitudinal support directly to patients” (pharmaphorum). Rock Health describes drugmakers “building out digital pathways that connect patients directly to care” (Rock Health, archived copy), and Arnold & Porter notes that platforms “through which patients purchase prescription drugs directly from manufacturers, often following a telehealth encounter, have expanded rapidly in recent years” (Arnold & Porter).

They are not one model. Rock Health separates “Full-service platforms such as LillyDirect and PfizerForAll” that “integrate prescribing, payment, and care navigation” from “targeted programs such as AstraZeneca Direct” that “focus on affordability and access” (Rock Health, archived copy).

Which drugmakers run direct-to-patient programs?

L.E.K. Consulting's 2026 report on direct-to-consumer platforms lists 11 in its Figure 1, “Pharma DTC platform trend” (L.E.K.). Every row is marked for cash payment and partner pharmacy delivery. Names are as L.E.K. prints them; it shades the first three as end-to-end platforms.

Platform (as L.E.K. names it)Focus areas L.E.K. listsTelehealth HCP finderInsurance payEnd-to-end platform
LillyDirectObesity, type 2 diabetes, migraineYesYesYes
NovoCare PharmacyObesityYesNot markedYes
PfizerForAllCOVID-19, migraine, vaccinesYesYesYes
Eliquis 360 SupportStroke prevention in atrial fibrillationNot markedYesNot marked
AmgenNowHypercholesterolemiaNot markedNot markedNot marked
AstraZeneca DirectType 2 diabetes, chronic kidney disease, heart failure, asthma, fluNot markedYesNot marked
Novartis (no public platform name)Plaque psoriasisNot markedYesNot marked
Bristol Myers Squibb Patient ConnectPlaque psoriasisNot markedNot markedNot marked
Synthroid DeliversHypothyroidismNot markedNot markedNot marked
Boehringer Ingelheim AccessCOPDNot markedYesNot marked
Genentech (no public platform name)InfluenzaNot markedYesNot marked

When did the major programs launch?

Rock Health's November 10, 2025 piece gives the order: “Eli Lilly’s LillyDirect came first in early 2024, followed by Pfizer’s PfizerForAll in the fall of 2024, and Novo Nordisk’s NovoCare earlier this year” (Rock Health, archived copy). The dated milestones since then:

  • September and October 2025. AstraZeneca Direct and Boehringer Ingelheim's Access (September), a Novartis program (September, platform name not specified) and AmgenNow (October), per Rock Health (Rock Health, archived copy).
  • January 27, 2026. The HHS Office of Inspector General issues its Special Advisory Bulletin on manufacturer direct-to-consumer sales (OIG bulletin).
  • February 5, 2026. TrumpRx.gov launches (White House).
  • March 31, 2026. Novo Nordisk launches a subscription program for cash-paying patients, offered “through telehealth providers Ro, WeightWatchers and LifeMD” (Managed Healthcare Executive).
  • April 16, 2026. The Digital Medicine Society (DiMe) launches “Optimizing Direct-to-Patient (DTP) Strategies for Pharma” with “Leading pharma organizations” and founding partners (DiMe).

How does TrumpRx fit with manufacturer programs?

TrumpRx.gov is a government website that points cash-paying patients to manufacturers' offers. The White House fact sheet says the launch featured “drugs made by the first five manufacturers [...] AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer,” and that patients with valid prescriptions can access savings through coupons “or through channels set up by the manufacturer and integrated into TrumpRx.gov” (White House).

The OIG bulletin describes TrumpRx as “a platform to connect patients seeking lower cost prescription drugs with direct-to-consumer (DTC) programs offered by manufacturers and other private companies” (OIG bulletin). DiMe's release reports that a CMS official, Chris Klomp, “clarified that TrumpRx is a cash-pay model not intended for most Americans with insurance” (DiMe).

Who does what inside a direct-to-patient program?

Most programs are a chain of partners. L.E.K. writes that “Manufacturers increasingly rely on ecosystems of specialized partners spanning telehealth, payments, pharmacy and logistics” and that “No single organization can deliver all capabilities at scale” (L.E.K.). King & Spalding explains one reason: “state medical practice and pharmacy licensure requirements generally restrict who may dispense prescription drugs to patients directly” (King & Spalding). L.E.K. breaks the journey into five modules; the last column shows the step a partner could report for measurement:

StepWhat L.E.K. says it coversEvent a partner could report
Intake and triage“Consumer-facing onboarding portals, eligibility screening and telehealth scheduling”Visit
Clinical review and prescribing“Independent virtual medical groups and e-prescribing systems”Consult, prescription
Coverage navigation and payment“Benefits verification, cash-pay calculators, affordability programs and payment processing”Counted in the paid fill
Pharmacy routing and fulfillment“Specialized mail-order or hybrid pharmacies supporting insured and self-pay flows”Paid fill
Delivery, refills and support“Home delivery or retail pickup, refill automation, and adherence support”Refills at month 3 and month 6

What does the OIG's January 2026 bulletin cover?

On January 27, 2026, the HHS Office of Inspector General issued a Special Advisory Bulletin that “addresses the application of the Federal anti-kickback statute to a pharmaceutical manufacturer’s offer and sale of prescription drugs through a DTC program” to cash-paying patients, including people enrolled in federal health care programs such as Medicare and Medicaid (OIG bulletin). It describes characteristics that, in OIG's view, make such a sale low risk:

  • Independent prescriber. “The individual has a valid prescription from an independent, third-party prescriber.”
  • No insurance claims. “no claims for these drugs are submitted to any insurer, including any Federal health care program”
  • No cross-marketing. The manufacturer “does not use the DTC program for one product as a vehicle to market other federally reimbursable products.”
  • No strings. The program price is not conditioned on any future purchases.
  • Stability. The drug stays available through the program “for at least one full plan year.”
  • No controlled substances. Controlled substances are not offered through the program.

The bulletin adds that it “would be prudent” for manufacturers to set up ways to communicate with an enrollee's plan to support drug utilization review, and stresses that a determination under the statute “can be made only through a case-by-case assessment of all relevant facts and circumstances, including the intent of the parties” (OIG bulletin). Arnold & Porter notes that “OIG frames these factors as risk-reducing, not dispositive” (Arnold & Porter).

What it leaves out matters for programs built on partners. The bulletin “addresses only the DTC sales transaction” between the manufacturer and the cash-paying patient and “does not address the application of the Federal anti-kickback statute to any arrangements that the manufacturer may have with physicians, pharmacies, pharmacy benefit managers, telemedicine vendors, marketers, or other individuals or entities” (OIG bulletin). King & Spalding reads it the same way: “arrangements with telehealth providers who might write a prescription that could be fulfilled through a DTC program are not covered by the Special Advisory Bulletin” (King & Spalding). King & Spalding also flags that other parts of a program could raise beneficiary inducement questions “if the arrangement directs beneficiaries to certain providers (e.g., telehealth providers) or certain pharmacies,” and that ad and promotion rules still apply; see DTC pharma advertising in 2026.

This page is general information, not legal advice. Questions about prescribers, pharmacies, telehealth partners and marketing vendors in a specific program belong with a healthcare lawyer, so talk to your counsel before you set up or change any of those arrangements.

What does this mean for measuring a program?

Three things follow. First, cash sales sit outside insurance: the bulletin's low-risk characteristics include that no claims are submitted to any insurer, and HealthVerity notes cash-pay patients “can disappear from closed payer claims data even though treatment has not stopped” (HealthVerity). Second, the steps happen at partners, so that is where the events are. Third, reporting by partner should describe results, not direct patients: the same tools for every partner, with numbers in aggregate. Shared measures are still being defined: DiMe's initiative says it will “define how to measure patient access and affordability” (DiMe). For the HIPAA side of cash-pay partners, see does HIPAA apply to cash-pay telehealth companies.

How Curve Compliance helps

Curve Compliance receives outcomes from other systems through incoming webhooks and offline conversion uploads from a CRM or EHR, and credits each to the original ad click. Applied to a direct-to-patient program, a telehealth or pharmacy partner can send step events such as consult, prescription and paid fill through an incoming webhook or a file upload. In this method, each partner sends a stripped-down event at each step, carrying the campaign that brought the patient, with no name or contact details.

Campaign Reporting puts Meta and Google Ads spend next to Curve-tracked conversions per platform and campaign, with five attribution models, so the drugmaker sees cost per paid fill by campaign. The drugmaker receives aggregate results by channel, campaign and partner. Partners connect once and see their own results, and the partner tools are open to every partner in the program. Curve strips PHI before data reaches an ad platform, signs a BAA on every plan, holds SOC 2 Type II, and its team does the setup, typically live in about a week, case by case. See Curve for pharma and medical devices and server-side conversion tracking, or book a call to map your program's partners and events.

For how a program can measure its results from ad to paid fill, see direct-to-patient pharma attribution.

Cash sales through these programs often leave no insurance claim; see why cash-pay patients disappear from claims data.

Sources, checked November 20, 2026: L.E.K. Consulting, 2026; Rock Health, November 10, 2025 (archived copy); White House fact sheet, February 5, 2026; OIG Special Advisory Bulletin, January 27, 2026; King & Spalding, February 2, 2026; Arnold & Porter, February 11, 2026; Managed Healthcare Executive, March 31, 2026; DiMe release, April 16, 2026; pharmaphorum, December 2, 2025; HealthVerity, January 14, 2026.

Frequently Asked Questions

What are pharma direct-to-patient programs?

They are drugmaker-run channels that let a patient pay a cash price for a prescription drug and get it filled and delivered through partner pharmacies, often after a telehealth visit. Examples include LillyDirect, NovoCare Pharmacy and PfizerForAll.

How many drugmakers run direct-to-patient programs?

L.E.K. Consulting's Figure 1 lists 11 manufacturer platforms (L.E.K.), and Rock Health named seven drugmakers' launches in its November 10, 2025 piece (Rock Health, archived copy). Counts differ by date and by what each source treats as a platform.

Is TrumpRx a direct-to-patient program?

TrumpRx.gov is a government website, launched February 5, 2026, that connects patients with prescriptions to manufacturers' offers through coupons or channels the manufacturer sets up (White House). The manufacturer programs behind it are the direct-to-patient programs.

Do direct-to-patient programs accept insurance?

Some do. In L.E.K.'s Figure 1, seven of the 11 platforms are marked for insurance pay as well as cash (L.E.K.). Cash purchases often sit outside the pharmacy benefit, so claims data may not see them (HealthVerity).

Does the OIG bulletin cover telehealth partners?

No. The bulletin says it does not address arrangements a manufacturer may have with physicians, pharmacies, pharmacy benefit managers, telemedicine vendors or marketers (OIG bulletin), and King & Spalding notes telehealth provider arrangements are not covered (King & Spalding).

Are direct-to-patient programs only for obesity drugs?

No. L.E.K. lists platforms for migraine, COVID-19, vaccines, stroke prevention in atrial fibrillation, hypercholesterolemia, COPD, plaque psoriasis, hypothyroidism and influenza alongside obesity (L.E.K.).

How can a drugmaker measure a direct-to-patient program?

Measure at the partners: each telehealth and pharmacy partner sends a small event at each step, carrying the campaign that brought the patient and no name or contact details. Matched to ad spend, those events give cost per paid fill by campaign and aggregate results by channel, campaign and partner.

Talk to Curve Compliance

Book a call. Planning how to measure a direct-to-patient program? In this method, partners send step events that carry the campaign, and the drugmaker receives aggregate results by channel, campaign and partner. Curve signs a BAA on every plan and its team does the setup. Book a call with Curve.